Brookline Capital Management reiterated their hold rating on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research note issued to investors on Thursday, Marketbeat reports.
A number of other research firms also recently commented on ONCT. HC Wainwright dropped their price objective on Oncternal Therapeutics from $19.00 to $18.00 and set a buy rating for the company in a report on Monday, August 12th. StockNews.com initiated coverage on Oncternal Therapeutics in a report on Sunday, September 8th. They set a hold rating for the company. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of Hold and a consensus target price of $20.00.
View Our Latest Analysis on ONCT
Oncternal Therapeutics Price Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($2.89) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.03) by $0.14. Oncternal Therapeutics had a negative return on equity of 136.10% and a negative net margin of 1,948.70%. The company had revenue of $0.80 million for the quarter, compared to analyst estimates of $0.24 million. During the same quarter in the prior year, the company posted ($3.00) EPS. As a group, sell-side analysts expect that Oncternal Therapeutics will post -11.4 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Pasadena Private Wealth LLC purchased a new stake in Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 25,000 shares of the company’s stock, valued at approximately $190,000. Pasadena Private Wealth LLC owned about 0.84% of Oncternal Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 16.05% of the company’s stock.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
See Also
- Five stocks we like better than Oncternal Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- How to Capture the Benefits of Dividend Increases
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- High Flyers: 3 Natural Gas Stocks for March 2022
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.